Safety, Pharmacokinetics, and Food Effect of PS1 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I, double-blind, placebo-controlled, randomized, single- and
multiple-ascending dose study to evaluate new study intervention, PS1. PS1 is a potential
blood glucose control medication, which is developed by Pharmasaga Co. Ltd. planned for
treating type II diabetes mellitus (T2DM). This is a first-in-human study to evaluate the
safety, tolerability, pharmacokinetics (PK), and food effect of PS1 in healthy subjects.